Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test

Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal(XY) (Fetal Sex Determination) test by Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company’s second laboratory developed test powered by its SEQureDx(TM) technology.

Source: Sequenom